New hope for Tough-to-Treat breast cancer: experimental combo enters human trials
Disease control
Recruiting now
This study is testing the safety and effectiveness of a new drug, VS-6766, when combined with two existing breast cancer drugs (abemaciclib and fulvestrant). It is for people with advanced HR+/HER2- breast cancer that has worsened despite prior standard treatments. The goal is to…
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC